Latest Administration News

Rox Resources has advanced its Youanmi Gold Project with a $27 million capital raise and a major drilling campaign, positioning the company for production by late 2025.

Terramin's December 2024 quarterly report reveals major progress at its Tala Hamza Zinc Project with land acquisition and a $336 million EPC contract, while the Bird in Hand Gold Project faces a legal hurdle after the Supreme Court dismissed its mining lease application.

Viking Mines has unveiled a high-grade inferred mineral resource of 19,000 ounces at its historic First Hit Gold Mine, alongside ongoing drilling and a strong cash position following a recent capital raise.

Butn Limited reported a modest net cash increase from operating activities in the December 2024 quarter, ending with a strong cash balance of $16.8 million. The fintech company’s latest cash flow report reveals ongoing investment and notable payments to related parties.

Complii FinTech Solutions Ltd reports a robust Q2 FY25 with a $3.048 million cash balance, a net operational cash inflow, and a 12.9% year-on-year increase in Annual Recurring Revenue, driven by strategic divestment and focused growth initiatives.

Zelira Therapeutics has received a fourth funding tranche, bringing total investment to US$3.25 million to support FDA clinical trials of its HOPE® 1 cannabinoid medicine targeting irritability in autism spectrum disorder and Phelan-McDermid Syndrome.

Argosy Minerals Limited reported a net cash outflow in its December 2024 quarter, driven by exploration and evaluation expenses, ending with nearly $6 million in cash reserves.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.